Drug Profile
AK 1
Alternative Names: Actokine-1; AK1Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator ActoKine Therapeutics
- Class Antineoplastics; Chemoprotectants; Cytokines
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Chemotherapy-induced damage; Radiation injuries
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer(Adjuvant therapy) in USA
- 04 Nov 2017 No recent reports of development identified for preclinical development in Chemotherapy-induced-damage(Prevention) in USA
- 04 Nov 2017 No recent reports of development identified for preclinical development in Radiation-injuries(Prevention) in USA